[1] MARCHANT D J,BOYD J H,LIN D C,et al.Inflammation in myocardial diseases[J].Circulation Research,2012,110(1):126-144.
[2] SHARIF H,WANG L,WANG W L,et al.Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J].Nature,2019,570(7761):338.
[3] WANG H,ZHANG C,LIU J T,et al.Dopamine promotes the progression of AML via activating NLRP3 inflammasome and IL-beta[J].Human Immunology,2021,82(12):968-975.
[4] CHEN K W,DEMARCO B,HEILIG R,et al.Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly[J].Embo Journal,2019,38(10):e101638.
[5] CHANG Y P,KA S M,HSU W H,et al.Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy[J].J Cell Physiol,2015,230(7):1567-1579.
[6] JO E K,KIM J K,SHIN D M,et al.Molecular mechanisms regulating NLRP3 inflammasome activation[J].Cell Mol Immunol,2016,13(2):148-159.
[7] SCHMACKE N A,O'DUILL F,GAIDT M M,et al.IKKβ primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network[J].Immunity,2022,55:2271-2284.
[8] ZHANG Z R,VENDITTI R,RAN L,et al.Distinct changes in endosomal composition promote NLRP3 inflammasome activation[J].Nat Immunol,2023,24:30-41.
[9] WANG Y B,ZHANGS T,LIH Y,et al.Small-molecule modulators of toll-like receptors[J].Acc Chem Res,2020,5:1046-1055.
[10] ARCIPOWSKI K M,STUNZ L L,BISHOP G A.TRAF6 is a critical regulator of LMP1 functions in vivo[J].International Immunology,2014,26(3):149-158.
[11] WU H,ARRON J R.TRAF6,a molecular bridge spanning adaptive immunity,innate immunity and osteoimmunology[J].Bioessays,2003,25(11):1096-1105.
[12] HOYT L R,RANDALL M J,ATHER J L,et al.Mitochondrial ROS induced by chronic ethanol exposure promote hyper-activation of the NLRP3 inflammasome[J].Redox Biology,2017,12:883-896.
[13] HESSE J,LEBERLING S,BODEN E,et al.CD73-derived adenosine and tenascin-C control cytokine production by epicardium-derived cells formed after myocardial infarction[J].Faseb Journal,2017,31(7):3040-3053.
[14] HE Y,ZENG M Y,YANG D H,et al.NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J].Nat Immunol,2016,530(7590):354-357.
[15] SHARMA A,TATE M,MATHEW G,et al.Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications:therapeutic implications[J].Front Physiol,2018,9:114.
[16] ZHANG H,CHEN X,ZONG B,et al.Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation[J].J Cell Mol Med,2018,22(9):4437-4448.
[17] SHAH A,XIA L,GOLDBERG H,et al.Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase,Nox4,in mesangial cells[J].J Biol Chem,2013,288(10):6835-6848.
[18] ZHOU R,TARDIVEL A,THORENS B,et al.Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J].Nat Immunol,2010(2):11.
[19] RAJAMAKI K,LAPPALAINEN J,OORNI K,et al.Cholesterol crystals activate the NLRP3 inflammasome in human macrophages:a novel link between cholesterol metabolism and inflammation[J].PLoS One,2010,5:e11765.
[20] HOSEINI Z,SEPAHVAND F,RASHIDI B,et al.NLRP3 inflammasome:its regulation and involvement in atherosclerosis[J].J Cell Physiol,2018,233(3):2116-2132.
[21] OKADA M,MATSUZAWA A,YOSHIMURA A,et al.The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation[J].J Biol Chem,2014,47:32926-32936.
[22] REN J D,WU X B,JIANG R,et al.Molecular hydrogen inhibits lipopolysaccharide-triggered NLRP3 inflammasome activation in macrophages by targeting the mitochondrial reactive oxygen species[J].BBA-Mol Cell Res,2016,1863(1):50-55.
[23] WANG F,WANG H,LIU X,et al.Neuregulin-1 alleviate oxidative stress and mitigate inflammation by suppressing NOX4 and NLRP3/caspase-1 in myocardial ischaemia-reperfusion injury[J].J Cell Mol Med,2021,25(3):1783-1795.
[24] WESTERTERP M,FOTAKIS P,OUIMET M,et al.Cholesterol efflux pathways suppress inflammasome activation,NETosis,and atherogenesis[J].Circulation,2018,138(9):898-912.
[25] HANSSON G K,HERMANSSON A.The immune system in atherosclerosis[J].Nat Immunol,2011,12(3):204-212.
[26] LIBBY P,HANSSON G K.Inflammation and immunity in diseases of the arterial tree players and layers[J].Circulation Research,2015,116(2):307-311.
[27] OURY C.CD36:linking lipids to the NLRP3 inflammasome,atherogenesis and atherothrombosis[J].Cellular Molecular Immunology,2014,11(1):8-10.
[28] REYES-SOFFER G,GINSBERG H N,BERGLUND L,et al.Lipoprotein(a):a genetically determined,causal,and prevalent risk factor for atherosclerotic cardiovascular disease:a scientific statement from the American Heart Association[J].Arterioscl Throm Vas,2022,42(1):E48-E60.
[29] BISKOU O,CASANOVA V,HOOPER K M,et al.The type Ⅲ intermediate filament vimentin regulates organelle distribution and modulates autophagy[J].PLoS One,2019,14:e0209665.
[30] KIM S Y,JEONG S J,PARK J H,et al.Plasma membrane localization of CD36 requires vimentin phosphorylation:a mechanism by which macrophage vimentin promotes atherosclerosis.Frontiers in cardiovascular medicine[J].Front Cardiovasc Med,2022,9:792717.
[31] THANKAM F G,KHWAJA B,NGUYEN M,et al.Acute exposure of minimally ox-LDL elicits survival responses by downregulating the mediators of NLRP3 inflammasome in cultured RAW 264.7 macrophages[J].J Biochem,2022,172(5):265-276.
[32] LIU C,WU J,JIA H Y,et al.Oncostatin M promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the NF-kappa B pathway in THP-1 macrophages and promotes the progression of atherosclerosis[J].Ann Transl Med,2022,10(8):456.
[33] SCHMACKE N A,O'DUILL F,GAIDT M M,et al.IKKβ primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network[J].Immunity,2022,55:2271-2284.
[34] SHI X,XIE W L,KONG W W,et al.Expression of the NLRP3 inflammasome in carotid atherosclerosis[J].J Stroke Cerebrovasc,2015,24(11):2455-2466.
[35] JIANG X,WANG F,WANG Y,et al.Inflammasome-driven interleukin-1 alpha and interleukin-1 beta production in atherosclerotic plaques relates to hyperlipidemia and plaque complexity[J].Jacc-Basic Transl Sci,2019,4(3):304-317.
[36] ZHENG F,XING S S,GONG Z S,et al.Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice[J].Mediators Inflamm,2014,2014:507208.
[37] SRINIVASAN N T,SCHILLING R J.Sudden cardiac death and arrhythmias[J].Arrhythm Electrophysiol Rev,2018,7(2):111-117.
[38] MIRCEA A A,RUSU M,LIEHN E A,et al.Promising therapies for atrial fibrillation and ventricular tachycardia[J].Int J Mol Sci,2022,23(20):12612.
[39] LEUNG L W,AKHTAR Z,KONTOGIANNIS C,et al.Economic evaluation of catheter ablation versus medical therapy for the treatment[J].Arrhythm Electrophysiol Rev,2022,11:e13.
[40] DOBREV D,HEIJMAN J,HIRAM R,et al.Inflammatory signalling in atrial cardiomyocytes:a novel unifying principle in atrial fibrillation pathophysiology[J].Nat Rev Cardiol,2023,20:145-167.
[41] ABBATE A,TOLDO S,MARCHETTI C,et al.Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J].Circ Res,2020,126(9):1260-1280.
[42] HEIJMAN J,MUNA A P,VELEVA T,et al.Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation[J].Circ Res,2020,127(8):1036-1055.
[43] LAKIN R,POLIDOVITCH N,YANG S,et al.Inhibition of soluble TNFα prevents adverse atrial remodeling and atrial arrhythmia susceptibility induced in mice by endurance exercise[J].J Mol Cell Cardiol,2019,129:165-173.
[44] SCOTT L J,ID O,AC F,et al.NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias[J].Cardiovasc Res,2021,117(7):1746-1759.
[45] SAWAYA S E,RAJAWAT Y S,RAMI T G,et al.Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor[J].AM J Physiol-Heart C,2007,292(3):H1561-H1567.
[46] SCOTT L Jr,LI N,DOBREV D.Role of inflammatory signaling in atrial fibrillation[J].International Journal of Cardiology,2019,287:195-200.
[47] KAWAGUCHI M,TAKAHASHI M,HATA T,et al.Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury[J].Circulation,2011,123(6):594-604.
[48] CAO X F,ZHANG F,ZHANG Y W.Effect of peroxisome proliferator-activated receptor γ activator rosiglitazone in rat hepatic ischemia-reperfusion injury and its mechanism[J].Acta Universitatis Medicinalis Nanjing,2007,52(4):287-290.
[49] JIA L,LI Y,XIAO C,et al.Angiotensin Ⅱ induces inflammation leading to cardiac remodeling[J].Front Bioscience-Landmark,2012,17:221-231.
[50] BRACEY N A,BECK P L,MURUVE D A,et al.The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β[J].Experimental Physiology,2013,98(2):462-472.
[51] DONG W L,YOUNG K I,SU K I.Renal sympathetic denervation induces acute myocardial inflammation through activation of caspase-1 and interleukin-1β[J].Journal of Life Science,2018,28(2):240-246.
[52] IKEDA S,ZABLOCKI D,SADOSHIMA J.The role of autophagy in death of cardiomyocytes[J].J Mol Cell Cardiol,2022,165:1-8.
[53] AMAN Y,SCHMAUCK-MEDINA T,HANSEN M,et al.Autophagy in healthy aging and disease[J].Nat Aging,2021,1(8):634-650.
[54] ALERS S,LOEFFLER A S,WESSELBORG S,et al.Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy:cross talk,shortcuts,and feedbacks[J].Mol Cell Biol,2012,32(1):2-11.
[55] AZAD M B,CHEN Y,HENSON E S,et al.Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3[J].Autophagy,2008,4(2):195-204.
[56] NAKAHIRA K,HASPEL J A,RATHINAM V A K,et al.Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome[J].Nat Immunol,2011,12(3):222-230.
[57] SALMINEN A,KAARNIRANTA K,KAUPPINEN A.Inflammaging:disturbed interplay between autophagy and inflammasomes[J].Aging-Us,2012,4(3):166-175.
[58] HARRIS J,DEEN N,ZAMANI S,et al.Mitophagy and the release of inflammatory cytokines[J].Mitochondrion,2018,41:2-8.
[59] PINEDA-RAMIREZ N,AGUILERA P.Resveratrol as an inductor of autophagy:is there a unique pathway of activation?[J].Neural Regeneration Research,2021,16(1):101-103.
[60] MARIN-AGUILAR F,CASTEJON-VEGA B,ALCOCER-GOMEZ E,et al.NLRP3 inflammasome inhibition by MCC950 in aged mice improves health via enhanced autophagy and PPAR alpha activity[J].J Gerontol A-Biol,2020,75(8):1457-1464.
[61] RAZANI B,FENG C,COLEMAN T,et al.Autophagy links inflammasomes to atherosclerotic progression[J].Cell Metabolism,2012,15(4):534-544.
[62] GUO F X,WU Q,LI P,et al.The role of the lncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling[J].Cell Death Differ,2019,26(9):1670-1687.
[63] GUO C,CHI Z,JIANG D,et al.Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages[J].Immunity,2018,49(5):842.
[64] WANG Z,CHEN D,GUAN D,et al.Material properties of phase-separated TFEB condensates regulate the autophagy-lysosome pathway[J].J Cell Biol,2022,221(5):e202112024.
[65] BHATTACHARYYA B,PANDA D,GUPTA S,et al.Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin[J].Med Res Rev,2008,28(1):155-183.
[66] AKODAD M,FAUCONNIER J,SICARD P,et al.Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model[J].Int J Cardiol,2017,240:347-353.
[67] SUZUKI K,MURTUZA B,SMOLENSKI R T,et al.Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis[J].Circulation,2001,104(12 Suppl 1):1308-1313.
[68] ABBATE A,TRANKLE C R,BUCKLEY L F,et al.Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction[J].J Am Heart Assoc,2020,9(5):e014941. |
